All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Cosmo Pharmaceuticals receives European Commission approval for Winlevi clascoterone cream treating acne vulgaris in adults, adolescents
Small molecule, dermatological, androgen receptor inhibitor, acne vulgaris, topical therapy - Read more

THE GOOD
Business Development & Partnerships

Samsung Bioepis, Phrontline Biopharma partner on dual-payload ADC development with undisclosed financials
Licensing deal, oncology, antibody-drug conjugate, co-development, milestone payments - Read more

Iambic, Jazz partner to test IAM1363-zanidatamab combination in HER2-positive breast cancer
Research collaboration, oncology, small molecule, antibody - Read more

Takeda, Innovent Biologics partner on late-stage oncology medicines IBI363, IBI343 for solid tumors globally
Licensing deal, oncology, global, solid tumors, late-stage development, commercialization - Read more

PRESENTED BY YOU?
Get the attention of 2300+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

✅ More Good News ✅

THE GOOD
Clinical Trials

GSK and Spero report positive Ph3 results for oral tebipenem HBr in complicated urinary tract infections
Small molecule, infectious disease, antibiotic, urinary tract infection, antimicrobial resistance - Read more

Nxera HTL0039732 EP4 antagonist shows promising Ph1 results in advanced solid tumours, advances to Ph2a
Small molecule, cancer, EP4 antagonist, solid tumors, combination therapy, checkpoint inhibitor - Read more

AbbVie's Rinvoq beats Humira in Ph3 rheumatoid arthritis trial, achieving double response rates in JAK inhibitor switch study
Small molecule, autoimmune, JAK inhibitor, rheumatoid arthritis, TNF inhibitor - Read more

THE GOOD
Company Launches

Elevara Medicines launches with $70M Series A, licenses Teijin Pharma’s CDK4/6 inhibitor ELV001 to advance phase 2 rheumatoid arthritis trial
Autoimmune, small molecule, rheumatoid arthritis, clinical-stage - Read more

THE GOOD
Fundraises

Vertero raises $20M Series D, Parkinson's candidate targeting gut-brain microbial amyloids
Neurological, small molecule, Parkinson disease, clinical-stage - Read more

Disc Medicine raises $225M public offering, commercializing treatments for blood diseases
Hematologic diseases, clinical-stage, rare disease, small molecule - Read more

CCTST raises $37.2M grant renewal, advancing clinical and translational science research
Translational science, clinical research platform, academic research center, multi-disease - Read more

Chemify raises $50M Series B, automation platform for drug design/manufacturing
Small molecule, platform technology, automation, drug design, manufacturing - Read more

Minerva Neurosciences raises $200M private placement, advancing roluperidone through Phase 3 trial
Neurological, clinical-stage, small molecule, schizophrenia - Read more

Adaptyx raises $14M Seed, biowearables platform for continuous multi-analyte molecular monitoring
Biowearables, continuous monitoring, AI/ML platform, multi-analyte sensing - Read more

THE GOOD
Investments

India's ACG invests $200M to build first US empty-capsule manufacturing facility in Atlanta
Oral solid dosage, manufacturing, strategic, major transaction, operational - Read more

THE GOOD
Market Reports

Survey finds 72% of consumers interested in pharma direct-to-consumer drug sales despite insurance concerns
Direct-to-consumer sales, strategic, operational, financial, competitive - Read more

THE GOOD
Mergers & Acquisitions

Curewell Capital makes majority investment in Wilmington PharmaTech to expand US drug ingredient manufacturing capacity
Small molecule, strategic, major transaction, operational, manufacturing - Read more

THE GOOD
Product Launches

SK Biopharmaceuticals, Eurofarma launch AI-based epilepsy management platform joint venture Mentis Care
Joint venture, neurological, AI/ML, digital health, global - Read more

THE BAD
Clinical Trials

Alector's latozinemab fails Ph3 trial for progranulin-targeted frontotemporal dementia treatment despite biomarker success
Antibody, neurological, monoclonal antibody, frontotemporal dementia, progranulin, GRN mutation - Read more

Terns Pharmaceuticals reports negative Ph2 results for TERN-601 GLP-1 receptor agonist in obesity, halts development
Small molecule, metabolic, GLP-1 receptor agonist, obesity, liver toxicity - Read more

THE BAD
Company Shutdown

Galapagos winds down cell therapy business after failed sale, cutting 365 jobs
Cell therapy, strategic, operational, cost reduction - Read more

THE BAD
Regulatory

Kenvue opposes FDA petition seeking Tylenol pregnancy warnings over alleged autism link concerns
Small molecule, neurological, regulatory, defensive strategy - Read more

FDA reports death in patient taking Ascendis Pharma's hypoparathyroidism drug Yorvipath, stock drops 12%
Prodrug, rare disease, regulatory, safety concern - Read more

THE BAD
Strategic Plans

Novo Nordisk Foundation pushes to replace majority of board citing slow obesity market response
GLP-1 agonist, obesity, strategic, operational, corporate governance - Read more

Syncona withdraws wind-down plans, will return £250m ($335.1M) to shareholders from mature investments instead
Life sciences fund, strategic, financial, capital reallocation, investment - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here